[1]Patent:US2012/323010,2012,A1
[2]Patent:US2012/323010,2012,A1
[3]Patent:US2012/323010,2012,A1
[4]Patent:EP2657234,2013,A1
[5]Patent:WO2014/135930,2014,A1
[6]OrganicProcessResearchandDevelopment,2016,vol.20,p.1799-1805
[7]Patent:CN106831772,2017,A
[8]Patent:CN106866668,2017,A
[9]OrganicProcessResearchandDevelopment,2018,vol.22,p.267-272
[10]JournalofMedicinalChemistry,2018,vol.61,p.10340-10344
[1]Patent:US2012/323010,2012,A1
[2]Patent:US2012/323010,2012,A1
[3]Patent:US2012/323010,2012,A1
[4]OrganicProcessResearchandDevelopment,2018,vol.22,p.267-272
[5]Patent:CN108239089,2018,A
[6]Patent:CN107880042,2018,A
[7]OrganicProcessResearchandDevelopment,2018,vol.22,p.1738-1744
[1]Patent:US2012/323010,2012,A1
[2]Patent:US2012/323010,2012,A1
[3]Patent:US2012/323010,2012,A1
[4]Patent:US2012/323010,2012,A1
[5]Patent:US2012/323010,2012,A1
[6]Patent:US2012/323010,2012,A1
[7]Patent:US2012/323010,2012,A1
[8]Patent:US2012/323010,2012,A1
[9]Patent:US2012/323010,2012,A1
[10]Patent:US2012/323010,2012,A1
[11]Patent:US2012/323010,2012,A1
[12]Patent:US2012/323010,2012,A1
[1]Patent:US2012/323010,2012,A1
[2]Patent:US2012/323010,2012,A1
[3]Patent:US2012/323010,2012,A1
[4]Patent:US2012/323010,2012,A1
[5]Patent:US2012/323010,2012,A1
[6]Patent:US2012/323010,2012,A1
[7]Patent:CN106866668,2017,A
Title: Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam.
Journal: Antimicrobial agents and chemotherapy 20160301
Title: Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.
Journal: The Journal of biological chemistry 20130927
Title: Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20120717
Title: Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole.
Journal: International journal of antimicrobial agents 20120601
Title: In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Journal: International journal of antimicrobial agents 20120101
Title: New Delhi metallo-β-lactamase (NDM-1): an update.
Journal: Journal of chemotherapy (Florence, Italy) 20111001
Title: In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
Journal: The Journal of antimicrobial chemotherapy 20101101
Title: In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.
Journal: The Journal of antimicrobial chemotherapy 20090801
Title: Ehmann DE, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8.
Title: Livermore DM, et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother. 2012 Jun;67(6):1354-8.
Title: Berkhout J, et al. Pharmacokinetics and penetration of GR20263 and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304.
Title: Zhang W, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018 Nov 21;7:142.
